130 related articles for article (PubMed ID: 37422592)
41. Burkitt lymphoma in children: the Israeli experience.
Eldar AH; Futerman B; Abrahami G; Attias D; Barak AB; Burstein Y; Dvir R; Gabriel H; Horovitz J; Kapelushnik J; Kaplinsky H; Miskin H; Sthoeger D; Toren A; Vilk-Revel S; Weintraub M; Yaniv I; Linn S; Arush MB
J Pediatr Hematol Oncol; 2009 Jun; 31(6):428-36. PubMed ID: 19648792
[TBL] [Abstract][Full Text] [Related]
42. Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies.
Della Rocca AM; Leonart LP; Ferreira VL; Tonin FS; Steffenello-Durigon G; Del Moral JAG; Fernandez-Llimos F; Pontarolo R
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):514-525. PubMed ID: 33947633
[TBL] [Abstract][Full Text] [Related]
43. A novel prognostic index for sporadic Burkitt lymphoma in adult patients: a real-word multicenter study.
Chen MT; Pan F; Chen YC; Zhang W; Lv HJ; Wang Z; Hong HM; Fang XJ; Wang YW; Pan T; Zou LQ; Guo HQ; Xie K; Chen LM; Li XQ; Yao YY; Chen ZG; Weng HW; Li XD; Shen YY; Zhou H; Xue HW; Zhang HL; Huang H; Lin TY
BMC Cancer; 2022 Jan; 22(1):45. PubMed ID: 34996395
[TBL] [Abstract][Full Text] [Related]
44. Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China.
Wang C; Liu J; Lei H; Li Y; Wu J; Guo B; Hu R; Liu T; Wu J; Ding Y; Hu C; Liang S; Xiao C; Liang X; Huang D; Yang T; Zhang W; Yang Z; Li J; Nan Y; Li Q; Xiang Y; Li Z; Wu Y; Liu Y
J Cell Mol Med; 2022 Oct; 26(19):5067-5077. PubMed ID: 36056692
[TBL] [Abstract][Full Text] [Related]
45. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
46. Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma.
Hester CA; Karbhari N; Rich NE; Augustine M; Mansour JC; Polanco PM; Porembka MR; Wang SC; Zeh HJ; Singal AG; Yopp AC
Cancer; 2019 Oct; 125(19):3428-3436. PubMed ID: 31299089
[TBL] [Abstract][Full Text] [Related]
47. Status and prognostic nomogram of patients with Burkitt lymphoma.
Lu J; Tan H; Li B; Chen S; Xu L; Zou Y
Oncol Lett; 2020 Jan; 19(1):972-984. PubMed ID: 31897210
[TBL] [Abstract][Full Text] [Related]
48. Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine.
Arshi A; Sharim J; Park DY; Park HY; Yazdanshenas H; Bernthal NM; Shamie AN
Spine J; 2017 May; 17(5):645-655. PubMed ID: 27856382
[TBL] [Abstract][Full Text] [Related]
49. Treatment at Twilight: An Analysis of Therapy Patterns and Outcomes in Adults 80 Years and Older With Advanced or Metastatic NSCLC.
Burns EA; Chen WH; Mathur S; Kieser RB; Zhang J; Bernicker EH
JTO Clin Res Rep; 2023 Oct; 4(10):100570. PubMed ID: 37822698
[TBL] [Abstract][Full Text] [Related]
50. Racial and Ethnic Disparities in the Pediatric Hodgkin Lymphoma Population.
Grubb WR; Neboori HJ; Diaz AD; Li H; Kwon D; Panoff J
Pediatr Blood Cancer; 2016 Mar; 63(3):428-35. PubMed ID: 26524117
[TBL] [Abstract][Full Text] [Related]
51. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
52. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
[TBL] [Abstract][Full Text] [Related]
53. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
[TBL] [Abstract][Full Text] [Related]
54. Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.
Wästerlid T; Jonsson B; Hagberg H; Jerkeman M
Leuk Lymphoma; 2011 Nov; 52(11):2090-6. PubMed ID: 21718134
[TBL] [Abstract][Full Text] [Related]
55. A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race.
Shah H; Jang H; Kim S; Halwani AS
Br J Haematol; 2023 Mar; 200(5):579-586. PubMed ID: 36400571
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study.
Silva WFD; Garibaldi PMM; Rosa LID; Bellesso M; Clé DV; Delamain MT; Rego EM; Pereira J; Rocha V
Leuk Res; 2020 Feb; 89():106287. PubMed ID: 31864677
[TBL] [Abstract][Full Text] [Related]
57. Disparities in Adolescent and Young Adult Sarcoma Survival: Analyses of the Texas Cancer Registry and the National SEER Data.
Avila JC; Livingston JA; Rodriguez AM; Kirchhoff AC; Kuo YF; Kaul S
J Adolesc Young Adult Oncol; 2018 Dec; 7(6):681-687. PubMed ID: 30096005
[TBL] [Abstract][Full Text] [Related]
58. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?
Guech-Ongey M; Simard EP; Anderson WF; Engels EA; Bhatia K; Devesa SS; Mbulaiteye SM
Blood; 2010 Dec; 116(25):5600-4. PubMed ID: 20813897
[TBL] [Abstract][Full Text] [Related]
59. Destitution, treatment adherence and survival of children with Burkitt lymphoma in a twinning programme in Northwest Cameroon.
Afungchwi GM; Hesseling P; van Elsland SL; Kouya F; Kruger M
Pediatr Blood Cancer; 2019 Dec; 66(12):e27946. PubMed ID: 31436364
[TBL] [Abstract][Full Text] [Related]
60. Racial/ethnic disparities in survival among men diagnosed with prostate cancer in Texas.
White A; Coker AL; Du XL; Eggleston KS; Williams M
Cancer; 2011 Mar; 117(5):1080-8. PubMed ID: 21351084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
